Gout combined with chronic kidney disease
Conditions
Interventions
IL-1 Inhibitor Anti-inflammatory + Conventional Urate-Lowering Therapy Group:IL-1 Inhibitor Anti-inflammatory + Febuxostat 40 mg qd Urate-Lowering Therapy
Conventional Urate-Lowering Therapy Group Only:Febuxostat 40 mg qd for Urate-Lowering
Sponsors
SHANGHAI TENTH PEOPLES HOSPITAL
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1 Voluntarily sign the informed consent form before the start of the activities related to this trial, and be able to understand the procedures and methods of this trial, and be willing to strictly follow the clinical trial protocol to complete this trial; 2 Age between 18 and 75 years old (inclusive of both ends, based on the date of signing the informed consent form , regardless of gender; 3 At the time of enrollment, clearly diagnosed with gout (in accordance with the 2015 ACR/EULAR gout diagnosis criteria , and in the intermission period (patients have not experienced gout attacks for at least the past two weeks ; and have not used uric acid-lowering drugs for the past 4 weeks. 4 Patients with proteinuria (total 24-hour urine protein > 0.15g or (and UACR > 30 mg/g ; 5 Chronic kidney disease (CKD stage 3 or below: eGFR >= 60 mL/min/1.73m^2; 6 Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1 Secondary gout (such as after organ transplantation or due to hematological diseases ; 2 Severe cardiovascular or cerebrovascular diseases, malignant tumors (except for cured skin basal cell carcinoma or cervical carcinoma in situ ; 3 Currently experiencing active infection; 4 Have used other biologics or immunosuppressants within the last 3 months; 5 Have had a drug allergy; 6 Pregnant, breastfeeding, or planning to become pregnant; 7 Abnormal laboratory test results during screening: A. Abnormal white blood cell count or absolute neutrophil count with clinical significance; B. Total bilirubin > 1.5 times the upper limit of normal (ULN , alanine aminotransferase (AST > 3 times ULN, aspartate aminotransferase (ALT > 3 times ULN.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urine protein and creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in urinary protein levels between the two groups after 24 weeks;Improvement of proteinuria at 48 weeks; | — |
Countries
China
Contacts
Public ContactHaibing Chen
SHANGHAI TENTH PEOPLES HOSPITAL
Outcome results
None listed